CalciMedica (NASDAQ:CALC) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of CalciMedica (NASDAQ:CALC) in a research note released on Thursday morning, Benzinga reports. The brokerage currently has a $20.00 target price on the stock.

Separately, Oppenheimer restated an outperform rating and set a $14.00 price target on shares of CalciMedica in a research note on Monday, April 1st.

CalciMedica Trading Up 25.7 %

Shares of NASDAQ:CALC opened at $3.96 on Thursday. CalciMedica has a 12 month low of $1.75 and a 12 month high of $8.38. The company has a 50-day moving average price of $5.26 and a 200-day moving average price of $4.62. The company has a market cap of $42.57 million, a price-to-earnings ratio of -1.84 and a beta of 1.35.

CalciMedica (NASDAQ:CALC) last issued its earnings results on Monday, May 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.07. As a group, research analysts forecast that CalciMedica will post -2.05 EPS for the current fiscal year.

Hedge Funds Weigh In On CalciMedica

Institutional investors have recently bought and sold shares of the stock. Hudson Bay Capital Management LP bought a new stake in shares of CalciMedica in the third quarter worth about $432,000. BML Capital Management LLC increased its stake in shares of CalciMedica by 10.3% in the 1st quarter. BML Capital Management LLC now owns 160,424 shares of the company’s stock valued at $667,000 after purchasing an additional 15,000 shares during the last quarter. Finally, Meritage Portfolio Management grew its position in CalciMedica by 360.0% during the 4th quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock worth $132,000 after acquiring an additional 36,000 shares during the last quarter.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.